Brian Abrahams

Apr 30, 2026

On Apr 30, 2026, BIIB was given a Outperform rating by Brian Abrahams, with a target price of 222. The stock traded sideways with a -1.09% move, keeping the bullish thesis unresolved.

Apr 24, 2026

DMRA received a Outperform rating from Brian Abrahams on Apr 24, 2026, aiming for 40. Price action was muted, as shares hovered around 25.93 despite the bullish outlook.

Apr 10, 2026

On Apr 10, 2026, Brian Abrahams published a Outperform outlook on EVMN, with a target of 48. Market action contradicted the Buy thesis, as shares slipped to 23.63.

Apr 06, 2026

Brian Abrahams on Apr 06, 2026 assigned PHVS a Outperform rating, with a price target of 51. The Buy call aligned well with market performance, producing a gain of 5.82%.

Feb 26, 2026

Brian Abrahams issued a Outperform recommendation for ACAD on Feb 26, 2026, price target set at 31. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Feb 13, 2026

VRTX received a Outperform rating from Brian Abrahams on Feb 13, 2026, aiming for 546. The rating hasn’t played out as hoped, with the stock trading 12.54% below expectations.

Feb 12, 2026

On Feb 12, 2026, Brian Abrahams published a Outperform outlook on NBIX, with a target of 180. Shares gained 8.91%, underscoring the accuracy of the bullish outlook toward 180.

Jan 30, 2026

BCRX was rated Outperform by Brian Abrahams on Jan 30, 2026, with a price objective of 13. A bullish response from the market helped close the gap of 3.80 to the target.

Jan 29, 2026

On Jan 29, 2026, Brian Abrahams initiated coverage on NRIX with a Outperform rating and target of 30. Neutral price movement of -3.75% leaves room for interpretation.

Jan 23, 2026

Brian Abrahams issued a Outperform recommendation for DFTX on Jan 23, 2026, price target set at 36. Investors following the Buy call captured upside momentum, with shares now at 21.75.

Jan 23, 2026

On Jan 23, 2026, GHRS was evaluated by Brian Abrahams, who gave a Outperform rating and target of 40. This case illustrates how a timely bullish rating can translate into tangible gains of 29.65%.

Dec 16, 2025

Brian Abrahams rated KYMR as Outperform on Dec 16, 2025, setting a price target of 103. Shares have remained stable near 83.59, leaving the 103 target still in play.

Dec 01, 2025

NMRA received a Outperform rating from Brian Abrahams on Dec 01, 2025, aiming for 7. Price action was muted, as shares hovered around 2.31 despite the bullish outlook.

Nov 21, 2025

On Nov 21, 2025, Brian Abrahams published a Outperform outlook on CTNM, with a target of 22. Shares gained 29.22%, underscoring the accuracy of the bullish outlook toward 22.

Nov 13, 2025

Brian Abrahams on Nov 13, 2025 assigned CRBP a Outperform rating, with a price target of 53. The recommendation remains pending validation as shares consolidate around 10.52.

Nov 07, 2025

On Nov 07, 2025, Brian Abrahams reaffirmed CDTX with a Outperform rating, targeting 145. The recommendation was supported by strong follow-through as the stock rose from 221.38 to 221.38.

Nov 07, 2025

On Nov 07, 2025, Brian Abrahams initiated coverage on MNMD with a Outperform rating and target of 20. The stock’s climb of 76.84% since the call highlights the foresight in the rating.

Nov 04, 2025

On Nov 04, 2025, XENE was evaluated by Brian Abrahams, who gave a Outperform rating and target of 58. This case illustrates how a timely bullish rating can translate into tangible gains of 46.84%.

Nov 04, 2025

Brian Abrahams rated KPTI as Outperform on Nov 04, 2025, setting a price target of 19. The call has proven timely, with shares rising 64.60% toward the price target of 19.

Feb 03, 2025

On Feb 03, 2025, Brian Abrahams published a Outperform outlook on AXSM, with a target of 143. Shares gained 108.23%, underscoring the accuracy of the bullish outlook toward 143.

Jan 28, 2025

Brian Abrahams on Jan 28, 2025 assigned NAMS a Outperform rating, with a price target of 40. The Buy call aligned well with market performance, producing a gain of 39.21%.